Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)
China
· Delayed Price · Currency is CNY 48.05
-0.73 (-1.50%)
Apr 18, 2025, 2:45 PM CST
Jiangsu Hengrui Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 6,337 | 4,302 | 3,906 | 4,530 | 6,328 | Upgrade
|
| Depreciation & Amortization | 772.2 | 704.64 | 577.89 | 520.41 | 448.39 | Upgrade
|
| Other Amortization | 98.62 | 89.3 | 66.26 | 20.33 | 27.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | -5.4 | -3.16 | -5.47 | -3.37 | -2.98 | Upgrade
|
| Asset Writedown & Restructuring Costs | 4.94 | 76.21 | 131.24 | -117.52 | -19.02 | Upgrade
|
| Loss (Gain) From Sale of Investments | -132.5 | 35.62 | -533.84 | -169.57 | -339.96 | Upgrade
|
| Provision & Write-off of Bad Debts | -28.67 | -15.77 | 26.02 | -3.87 | 9.36 | Upgrade
|
| Other Operating Activities | 30.83 | 17.02 | -67.79 | -27.8 | -14.88 | Upgrade
|
| Change in Accounts Receivable | -375.7 | 2,036 | -2,285 | -868.27 | -3,486 | Upgrade
|
| Change in Inventory | -135.63 | 129.11 | -52.68 | -631.22 | -173.62 | Upgrade
|
| Change in Accounts Payable | 671.41 | 315.32 | -511.05 | 809.7 | 222.12 | Upgrade
|
| Change in Other Net Operating Assets | 209.26 | 55.47 | 34.98 | 253.16 | 414.48 | Upgrade
|
| Operating Cash Flow | 7,423 | 7,644 | 1,265 | 4,219 | 3,432 | Upgrade
|
| Operating Cash Flow Growth | -2.89% | 504.12% | -70.01% | 22.93% | -10.08% | Upgrade
|
| Capital Expenditures | -1,969 | -1,484 | -1,992 | -1,665 | -554.33 | Upgrade
|
| Sale of Property, Plant & Equipment | 21.9 | 20.18 | 20.21 | 16.11 | 3.56 | Upgrade
|
| Divestitures | - | - | 36.05 | - | - | Upgrade
|
| Investment in Securities | -17.2 | 2,590 | 2,160 | 842.49 | 2,007 | Upgrade
|
| Other Investing Activities | 52.51 | 95.51 | 166.49 | 259.77 | 341.42 | Upgrade
|
| Investing Cash Flow | -1,912 | 1,222 | 390.29 | -546.26 | 1,798 | Upgrade
|
| Short-Term Debt Issued | - | - | 1,260 | - | - | Upgrade
|
| Long-Term Debt Issued | 799.91 | 21.1 | - | - | - | Upgrade
|
| Total Debt Issued | 799.91 | 21.1 | 1,260 | - | - | Upgrade
|
| Long-Term Debt Repaid | -847.28 | -1,315 | -36.28 | -31.05 | - | Upgrade
|
| Net Debt Issued (Repaid) | -47.38 | -1,294 | 1,224 | -31.05 | - | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 1,171 | Upgrade
|
| Repurchase of Common Stock | -228.43 | -827.26 | -1,066 | -235.16 | -11.98 | Upgrade
|
| Common Dividends Paid | -1,275 | -1,023 | -1,016 | -1,066 | -1,017 | Upgrade
|
| Other Financing Activities | - | - | 538.86 | 334.14 | 149.1 | Upgrade
|
| Financing Cash Flow | -1,551 | -3,144 | -318.77 | -998.32 | 291.19 | Upgrade
|
| Foreign Exchange Rate Adjustments | 7.4 | 12.53 | 80.5 | -16.87 | -89.08 | Upgrade
|
| Net Cash Flow | 3,968 | 5,734 | 1,417 | 2,657 | 5,432 | Upgrade
|
| Free Cash Flow | 5,454 | 6,160 | -726.91 | 2,554 | 2,878 | Upgrade
|
| Free Cash Flow Growth | -11.47% | - | - | -11.24% | -11.61% | Upgrade
|
| Free Cash Flow Margin | 19.49% | 26.99% | -3.42% | 9.86% | 10.38% | Upgrade
|
| Free Cash Flow Per Share | 0.86 | 0.97 | -0.11 | 0.40 | 0.45 | Upgrade
|
| Cash Income Tax Paid | 2,290 | 1,568 | 1,631 | 1,607 | 3,022 | Upgrade
|
| Levered Free Cash Flow | 4,410 | 4,866 | -2,030 | 1,151 | 2,583 | Upgrade
|
| Unlevered Free Cash Flow | 4,414 | 4,869 | -2,026 | 1,154 | 2,583 | Upgrade
|
| Change in Net Working Capital | -1,255 | -2,796 | 2,620 | 219.28 | 1,571 | Upgrade
|
Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.